Contemporary trends in the diagnosis and management of pulmonary arterial hypertension an initiative to close the care gap

Chest

Volumn 143, Issue 2, 2013, Pages 324-332

  McLaughlin, Vallerie V ^a   Langer, Anatoly ^b   Tan, Mary ^b   Clements, Philip J ^c   Oudiz, Ronald J ^d   Tapson, Victor F ^e   Channick, Richard N ^f   Rubin, Lewis J ^g  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b CANADIAN HEART RESEARCH CENTRE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE;

6 MIN WALK DISTANCE; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CLINICAL PRACTICE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER PROGRAM; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE SPECIFIC THERAPY; ELECTROCARDIOGRAM; ELECTRONIC DATA MANAGEMENT SYSTEM; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HEALTH CARE QUALITY; HEART CATHETERIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; LIVER FUNCTION TEST; LUNG ANGIOGRAPHY; LUNG FUNCTION TEST; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NEW YORK HEART ASSOCIATION CLASS; OXIMETRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SCREENING TEST; THERAPY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TWO DIMENSIONAL ECHOCARDIOGRAPHY; UNITED STATES; WALKING;

EID: 84873126341     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-3060     Document Type: Article

References (24)

1. Proceedings of the 4th World Symposium on Pulmonary Hypertension, February 2008, Dana Point, California, USA. J Am Coll Cardiol. 2009; 54 (suppl 1): S1-S117.
2. Barst RJ, Rubin LJ, Long WA, et al; The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334 (5): 296-302.
3. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000; 132 (6): 425-434.
4. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358 (9288): 1119-1123.
5. Simonneau G, Barst RJ, Galie N, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165 (6): 800-804.
6. Olschewski H, Simonneau G, Galiè N, et al; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347(5): 322-329.
7. Barst RJ, Langleben D, Frost A, et al; STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 169 (4): 441-447.
8. Galié N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46 (3): 529-535.
9. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54 (suppl 1): S55-S66.
10. McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53 (17): 1573-1619.
11. McGoon M, Gutterman D, Steen V, et al; American College of Chest Physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126(suppl 1): 14S-34S.
12. Galiè N, Hoeper MM, Humbert M, et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30 (20): 2493-2537.
13. McNeil K, Dunning J. Chronic thromboembolic pulmonary hypertension (CTEPH). Heart. 2007; 93 (9): 1152-1158.
14. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173 (9): 1023-1030.
15. Badesch DB, Abman SH, Ahearn GS, et al; American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126 (suppl 1): 35S-62S.
16. Barst RJ. Evaluation and treatment for angina in pulmonary arterial hypertension. Am J Med. 2004; 116 (6): 427-428.
17. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010; 137 (2): 376-387.
18. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007; 30 (6): 1103-1110.
19. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122 (2): 164-172.
20. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122 (2): 156-163.
21. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg- Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010; 35 (5): 1079-1087.
22. Vazquez AA, Aduen JF, Aduen P, Heckman MG, Burger CD. Should all patients with pulmonary hypertension undergo HIV serologic testing? South Med J. 2011; 104 (8): 589-592.
23. Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007; 48 (5): 680-684.
24. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111 (23): 3105-3111.